Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Glossary:TAG-00261-Una-ner

From GxPlex

Revision as of 13:51, 16 July 2026 by Gxplex admin (talk | contribs) (1 revision imported)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search


Glossary > Unanticipated device effect

Unanticipated device effect
Tag-ID TAG-00261-Una-ner
English Unanticipated adverse device effect / Unanticipated serious adverse device effect
EN Abbr. UADE / USADE
French Effet indésirable grave inattendu d'un dispositif médical / Effet indésirable grave inattendu et imprévu
FR Abbr. UADE / USADE
German Unerwarteter schwerwiegender GerĂ€tezwischenfall / Unerwartete schwerwiegende unerwĂŒnschte GerĂ€tewirkung
DE Abbr. UADE / USADE

References

 ScopeDocument partLanguageDocument
ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 3.51MD3.51ENISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020
USA 21 CFR Part 812 09-Apr-2025 § 812.150 (a) (1)MD§ 812.150 (a) (1)ENUSA 21 CFR Part 812 09-Apr-2025
USA 21 CFR Part 812 09-Apr-2025 § 812.150 (a) (4)MD§ 812.150 (a) (4)ENUSA 21 CFR Part 812 09-Apr-2025
USA 21 CFR Part 812 09-Apr-2025 § 812.150 (b) (1)MD§ 812.150 (b) (1)ENUSA 21 CFR Part 812 09-Apr-2025
USA 21 CFR Part 812 09-Apr-2025 § 812.3 (s)MD§ 812.3 (s)ENUSA 21 CFR Part 812 09-Apr-2025
USA 21 CFR Part 812 09-Apr-2025 § 812.46 (b)MD§ 812.46 (b)ENUSA 21 CFR Part 812 09-Apr-2025
USA 21 CFR Part 812 09-Apr-2025 § 812.46 (b) - (c)-001MD§ 812.46 (b) - (c)ENUSA 21 CFR Part 812 09-Apr-2025
USA 21 CFR Part 812 09-Apr-2025 § 812.46 (b) - (c)-002MD§ 812.46 (b) - (c)ENUSA 21 CFR Part 812 09-Apr-2025
USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection Jan-2009 III A. ; IV.GIII A. ; IV.ENUSA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection Jan-2009
USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection Jan-2009 Introduction ; III. B. ; EvaluationGIntroduction ; III. B. ; EvaluationENUSA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection Jan-2009
USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection Jan-2009 Introduction ; III. B. ; IV.GIntroduction ; III. B. ; IV.ENUSA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection Jan-2009